Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 | P21728 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.41 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | DAGLA | Q9Y4D2 | 2/20 | 0.39 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.38 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2373108 | 0.79 | ALOX15 (0.43) | DRD1ALOX15GFERADAM17ALDH3A1 | |
| SCHEMBL2373111 | 0.79 | SMN1; SMN2 (0.63) | DRD1ALOX15GFERADAM17ALDH3A1 | |
| SCHEMBL5335393 | 0.77 | CA1 (0.61) | ALDH1A1LMNASMN1; SMN2FFAR4PKM | |
| SCHEMBL5338319 | 0.76 | ALDH3A1 (0.43) | DRD1ALOX15GFERADAM17ALDH3A1 | |
| SCHEMBL5339117 | 0.76 | FFAR4 (0.54) | ADAM17HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL2371138 | 0.75 | FFAR4 (0.43) | DRD1ALOX15GFERADAM17ALDH3A1 | |
| SCHEMBL423265 | 0.74 | CA1 (0.57) | ALDH1A1MEN1KMT2APKM | |
| SCHEMBL2371139 | 0.73 | KDM4E (0.56) | ALDH1A1KITLMNASMN1; SMN2HTT | |
| SCHEMBL22954612 | 0.73 | HTR6 (0.54) | DRD1ALOX15GFERADAM17ALDH1A1 | |
| SCHEMBL5334789 | 0.72 | ALDH1A1 (0.59) | ALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030216571-A1 | Antiallergens; antiinflammatory agents | UBE INDUSTRIES, LTD. (JP) | 2003-11-20 | — | — | US | claimed |
| EP-1254897-A1 | TRICYCLIC COMPOUNDS | Ube Industries, Ltd. (JP) | 2002-11-06 | — | — | EP | claimed |
| US-7309718-B2 | Dibenzocycloheptene compound | UBE INDUSTRIES, LTD. (JP) | 2007-12-18 | — | — | US | disclosed |
| US-20040180884-A1 | Dibenzocycloheptene compound | UBE INDUSTRIES, LTD. (JP) | 2004-09-16 | — | — | US | disclosed |
| EP-1408033-A1 | DIBENZOCYCLOHEPTENE COMPOUND | Ube Industries, Ltd. (JP) | 2004-04-14 | — | — | EP | disclosed |
| US-20030216571-A1 | Antiallergens; antiinflammatory agents | UBE INDUSTRIES, LTD. (JP) | 2003-11-20 | — | — | US | disclosed |
| EP-1254897-A1 | TRICYCLIC COMPOUNDS | Ube Industries, Ltd. (JP) | 2002-11-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180884-A1 | Dibenzocycloheptene compound | LTB4R2, LTA4H, LTC4S | DRD1 145/4885ALOX15 13/4885GFER 859/4885 |
| US-20030216571-A1 | Antiallergens; antiinflammatory agents | CYSLTR2, CYSLTR1, LTC4S | DRD1 1038/4885ALOX15 9/4885GFER 252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.